Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): Study protocol for randomised controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  van Engelen, Baziel ^a   Abghari, Shaghayegh ^a   Aschrafi, Armaz ^a   Bouman, Sachas ^a   Cornelissen, Yvonne ^a   Glennon, Jeffrey ^a   Groot, Perry ^a   Heerschap, Arend ^a   Heskamp, Linda ^a   Heskes, Tom ^a   Kapusta, Katarzyna ^a   Klerks, Ellens ^a   Knoop, Hans ^a   Maas, Daphnes ^a   Okkersen, Kees ^a   Poelmans, Geert ^a   Rahmadi, Ridho ^a   van Nimwegen, Marlies ^a   Gorman, Grainne ^b   Moreno, Cecilia Jimenez ^b   Lochmüller, Hanns ^b   Trenell, Mike ^b   van Laar, Sandra ^b   Wood, Libby ^b   Schoser, Benedikt ^c   Wenninger, Stephan ^c   Schüller, Angela ^c   Auguston, Rémie ^d   Baptiste, Lignier ^d   Barau, Caroline ^d   Bassez, Guillaume ^d   Chevalier, Pascales ^d   Couppey, Florence ^d   Delmas, Stéphanie ^d   Deux, Jean François ^d   Dogan, Celines ^d   Hamadouche, Amira ^d   Hankiewicz, Karolina ^d   Lhermet, Laures ^d   Minier, Lisa ^d   Rialland, Amandines ^d   Schmitz, David ^d   Monckton, Darren G ^e   Cumming, Sarah A ^e   Adam, Berit ^e   Donnan, Peter ^f   Hannah, Michael ^f   Hogarth, Fiona ^f   Littleford, Roberta ^f   McKenzie, Emma ^f   Rauchhaus, Petra ^f   Wilkie, Erna ^f   Williamson, Jennifers ^f   Catt, Mike ^g   Dittrich, Julianes ^h   Schwalber, Ameli ^h   Treweek, Shaun ⁱ   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MUNICH   (Germany)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g Catt Sci LTD   (United Kingdom)

^h Catt Sci LTD ^*  (Germany)

ⁱ UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Aerobic exercise training; Cognitive behavioural therapy; DM1; Myotonic dystrophy type 1; Rare diseases

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHLORIDE CHANNEL; INSULIN RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 1; MICRORNA 133B; MICRORNA 206; MICRORNA 29; RYANODINE RECEPTOR 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TROPONIN T; UNCLASSIFIED DRUG;

ACCELEROMETER; ACTIVITY OF DAILY LIVING ASSESSMENT; AEROBIC EXERCISE; APATHY EVALUATION SCALE; ARTICLE; BECK DEPRESSION INVENTORY; BECK DEPRESSION INVENTORY FAST SCREEN; BLOOD SAMPLING; CARDIOVASCULAR MAGNETIC RESONANCE; CHECKLIST INDIVIDUAL STRENGTH SUBSCALE FATIGUE SEVERITY; COGNITIVE THERAPY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FATIGUE; FATIGUE AND DAYTIME SLEEPINESS SCALE; FRANCE; GERMANY; GOOD CLINICAL PRACTICE; HEREDITY; HUMAN; INDIVIDUALISED NEUROMUSCULAR QUALITY OF LIFE QUESTIONNAIRE; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; INTERVENTION STUDY; KINESIOTHERAPY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYOTONIC DYSTROPHY; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PEER REVIEW; PHYSICAL ACTIVITY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RARE DISEASE; RATING SCALE; SOMNOLENCE; STROOP TEST; UNITED KINGDOM; WALKING SPEED; CHECKLIST; CLINICAL PROTOCOL; CLINICAL TRIAL; EUROPE; EXERCISE TOLERANCE; FEMALE; GENETICS; MALE; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PROCEDURES; PSYCHOLOGY; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

CHECKLIST; CLINICAL PROTOCOLS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; EUROPE; EXERCISE THERAPY; EXERCISE TOLERANCE; FATIGUE; FEMALE; HUMANS; MALE; MYOTONIC DYSTROPHY; PATIENT SELECTION; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930663044     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0737-7     Document Type: Article

References (16)

1. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175-86. doi:10.1093/brain/awp236.
2. Norman AM, Floyd JL, Meredith AL, Harper PS. Presymptomatic detection and prenatal diagnosis for myotonic dystrophy by means of linked DNA markers. J Med Genet. 1989;26:750-4.
3. European Commission. European Commission Eurostat Yearbook 2011, 2011. Brussels (Belgium): European Commission; 2011.
4. Gagnon C, Noreau L, Moxley RT, Laberge L, Jean S, Richer L, et al. Towards an integrative approach to the management of myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry. 2007;78:800-6.
5. Kierkegaard M, Harms-Ringdahl K, Edström L, Widén Holmqvist L, Tollbäck A. Feasibility and effects of a physical exercise programme in adults with myotonic dystrophy type 1: a randomized controlled pilot study. J Rehabil Med. 2011;43:695-702.
6. Cup EH, Pieterse AJ, Ten Broek-Pastoor JM, Munneke M, van Engelen BG, Hendricks HT, et al. Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil. 2007;88:1452-64.
7. Voet NBM, Bleijenberg G, Padberg GW, van Engelen BGM, Geurts ACH. Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial. BMC Neurol. 2010;10:56.
8. Voet NBM, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BGM, Geurts ACH. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev. 2013, Issue 7. Art. No.: CD003907. doi:10.1002/14651858.CD003907.pub4.
9. Kalkman JS, Schillings ML, van der Werf SP, Padberg GW, Zwarts MJ, van Engelen BG, et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry. 2005;76:1406-9.
10. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007;62:571-9.
11. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994;38:383-92.
12. Hermans MC, Faber CG, De Baets MH, de Die-Smulders CE, Merkies IS. Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscul Disord. 2010;20:310-8.
13. Morales F, Couto JM, Higham CF, Hogg G, Cuenca P, Braida C, et al. Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity. Hum Mol Genet. 2012;21:3558-67.
14. Higham CF, Morales F, Cobbold CA, Haydon DT, Monckton DG. High levels of somatic DNA diversity at the myotonic dystrophy type 1 locus are driven by ultra-frequent expansion and contraction mutations. Hum Mol Genet. 2012;21:2450-63.
15. Janssen BH, Voet NB, Nabuurs CI, Kan HE, de Rooy JW, Geurts AC, et al. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS One. 2014;9:e85416.
16. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21:2917-30.